Sustained release Aricept and eribulin key near-term R&D projects for Eisai
This article was originally published in Scrip
Eisai expects a new high-dose, sustained release formulation to help sustain sales of its top product, the Alzheimer's disease therapy Aricept (donepezil), while the microtubule dynamics inhibitor eribulin will lead the Japanese firm's near-term push into the oncology sector.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.